Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective
treatment for ulcerative colitis after 52 weeks of treatment.